 Exploratory study evaluating effects of crofelemer on gut microbiome SAN FRANCISCO, CA ACCESSWIRE August 23, 2021 Napo Pharmaceuticals, the wholly-owned subsidiary of Jaguar Health, Inc. NASDAQ:JAGX today announced that an abstract associated with an exploratory clinical study on the effect of crofelemer Mytesi on the gastrointestinal microbiome in people living with HIVAIDS PLWHA has been submitted for consideration for presentation at IDWeek 2021, which takes place virtually from September 29 to October 3. Mytesi crofelemer is an antidiarrheal drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIVAIDS on antiretroviral therapy ART. 